<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335521">
  <stage>Registered</stage>
  <submitdate>20/05/2010</submitdate>
  <approvaldate>27/05/2010</approvaldate>
  <actrnumber>ACTRN12610000432011</actrnumber>
  <trial_identification>
    <studytitle>A randomised controlled trial of atomoxetine for adults with Attention Deficit Hyperactivity Disorder (ADHD)</studytitle>
    <scientifictitle>A randomised controlled trial of atomoxetine vs placebo for attentional lapses in adults with attention deficit hyperactivity disorder (ADHD)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Attention deficit hyperactivity disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Atomoxetine capsules (daily dose ranging from 60mg-120mg) for 10 weeks.  Starting dose is 60mg daily for all participants.  Dose may be increased after 2 weeks to 90mg or 120 mg depending on individual clinical response as judged by clinical assessment and rating scales.</interventions>
    <comparator>Identical looking placebo capsules daily for 10 weeks (microcellulose capsule)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Continuous Temporal Expectancy Task</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Stop Signal Task</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Spatial N-Back</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Contingent Capture Task</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Motor response reward task</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Connors Adult ADHD Rating Scale</outcome>
      <timepoint>Baseline, 2, 4, 6, 8 and 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sheehan Disability Scale</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>State-trait anxiety inventory</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Beck Depression Inventory</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>State-trait anger inventory</outcome>
      <timepoint>Baseline and 10 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Aged at least 18 years
Diagnosis of ADHD</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Current or past diagnosis of psychotic disorders, pervasive development disorders, intellectual impairment, 
2. History of serious neurologic illnesses including stroke, brain tumours, head trauma, multiple sclerosis, epilepsy, movement disorders or migraine in treatment
3. drug dependency on alcohol or illicit substances
4. Pregnancy or breast feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>4/06/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>68</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Queensland</primarysponsorname>
    <primarysponsoraddress>Brisbane QLD 4072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Eli Lilly</fundingname>
      <fundingaddress>Eli Lilly Australia Pty Ltd
Address: 112 Wharf Road
West Ryde NSW
2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Atomoxetine is an established treatment for ADHD.  Despite its routine use, little is understood how it influences brain functioning.  This study will test the effect of atomoxetine treatment on a range of brain functions relevant to ADHD.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Angela Dean</name>
      <address>The Queensland Brain Institute
QBI Building (#79)
Upland Rd
The University of Queensland
St Lucia, QLD 4072</address>
      <phone>+61 7 3346 3325</phone>
      <fax />
      <email>a.dean@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Angela Dean</name>
      <address>The Queensland Brain Institute
QBI Building (#79)
Upland Rd
The University of Queensland
St Lucia, QLD 4072</address>
      <phone>+61 7 3346 3325</phone>
      <fax />
      <email>a.dean@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Angela Dean</name>
      <address />
      <phone />
      <fax />
      <email>a.dean@uq.edu.au</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>